| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
GSK2245035 manufacturers
- GSK2245035
-
- $272.00
-
2026-07-27
- CAS:1207629-49-9
- Purity:
- Supply Ability: 10g
- GSK2245035
-
- $272.00
-
2026-07-27
- CAS:1207629-49-9
- Purity:
- Supply Ability: 10g
- GSK2245035
-
- $1230.00
-
2025-08-22
- CAS:1207629-49-9
- Purity:
- Supply Ability: 10g
|
| | GSK2245035 Basic information |
| Product Name: | GSK2245035 | | Synonyms: | GSK2245035;GSK2245035
(GSK 2245035;8H-Purin-8-one, 6-amino-7,9-dihydro-2-[(1S)-1-methylbutoxy]-9-[5-(1-piperidinyl)pentyl]-;6-Amino-2-((1-methylbutyl)oxy)-9-(5-(1-piperidinyl)pentyl)-7,9-dihydro-8H-purin-8-one;AYK003 NO | | CAS: | 1207629-49-9 | | MF: | C20H34N6O2 | | MW: | 390.52 | | EINECS: | 629-855-3 | | Product Categories: | | | Mol File: | 1207629-49-9.mol |  |
| | GSK2245035 Chemical Properties |
| Melting point | 207.4 °C | | density | 1.142±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 125 mg/mL (320.09 mM) | | form | A solid | | pka | 10.28±0.20(Predicted) | | color | Off-white to light yellow |
| | GSK2245035 Usage And Synthesis |
| Uses | GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma[1]. | | in vivo | GSK2245035 (i.n.; 0.03-1 mg/kg; 6 hours) makes dose-related increasing in IFNα levels in serum at doses of 0.3 mg/kg and above at the 2 h time point which had subsided at 6 h[1].
GSK2245035 (3, 30, 300, 3000 ng/kg; 6 hours) treatment can make plasma IP-10 provided the most sensitive biomarker of target engagement with raised levels of this chemokine detected at doses of 30 ng/kg and above in the cynomolgus monkey[1].
| Animal Model: | Female BALB/c mice[1] | | Dosage: | 0.03, 0.1, 0.3, 1 mg/kg | | Administration: | Intranasally (i.n.); 6 hours | | Result: | Dose-related increases in IFNα levels in serum were detected at doses of 0.3 mg/kg and above at the 2 h time point which had subsided at 6 h.
|
| | IC 50 | TLR7; IFNα: 9.3 (pEC50); CD40: 6.5 (pEC50) | | References | [1] Biggadike K, et al. Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma. J Med Chem. 2016 M DOI:10.1021/acs.jmedchem.5b01647 |
| | GSK2245035 Preparation Products And Raw materials |
|